The European medicines regulator said on Friday it will review safety information for Eisai and Biogen's Leqembi, nearly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results